Screener
Aclaris Therapeutics ACRS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Accounts payable | 2,355 | 4,107 |
| Accrued expenses and other liabilities | (3,098) | (10,643) |
| Deferred income | (1,826) | (1,795) |
| Net cash used in operating activities | (37,996) | (23,050) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (71) | (64) |
| Purchases of marketable securities | (60,598) | (29,926) |
| Proceeds from sales and maturities of marketable securities | 40,000 | 54,989 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's operating cash flow?
- Aclaris Therapeutics (ACRS) reported operating cash flow of -$19.85M in Q2 2026.
- How has Aclaris Therapeutics's operating cash flow changed year-over-year?
- Aclaris Therapeutics's operating cash flow decreased by 98.6% year-over-year, from -$9.99M to -$19.85M.
- What is the long-term trend for Aclaris Therapeutics's operating cash flow?
- Over 3 years (2021 to 2025), Aclaris Therapeutics's operating cash flow has grown at a -3.3% compound annual growth rate (CAGR), from -$52.13M to -$47.11M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Aclaris Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude